£20m pre-money

Investment Sought:
£5.8m for 19.1% equity
(Q3 2020)

Our mission is to enable earlier identification of complications of chronic disease enabling earlier intervention

Click here to register your interest

How Gendius_AI works?

  • Gendius has developed novel AI algorithms that predict an individuals risk of developing Chronic Kidney Disease or Cardiovascular disease over the next 5 years.
  • Gendius_AI enables earlier identification of patients at risk of complications resulting in earlier interventions by the healthcare team and patient.
  • These algorithms can be implemented using existing infrastructure or our award winning platform intellin.
  • Our Intellin platform was downloaded over 450,000 times in 2020 with over 60,000 monthly active users.

Transforming Chronic Disease Through AI

  • Global MSA with AstraZeneca and now seeing rollouts beyond the GCC beachhead market.
  • Heads of terms with Spirit Pharmacy, the UK’s leading NHS approved online pharmacy.
  • MoU in place with B Grimm, leading healthcare provider in Thailand.
  • Novel approach to using AI to predict an individual’s risk of developing complications.
  • Over 7.5m data points.
  • Over 2,200 patients followed over 10 years.
  • NHS CCG contracts.
  • Top-end experienced team with proven delivery.
  • Personalised risk prediction leading to earlier identification and earlier intervention.

The AI ‘Secret sauce’

We use our algorithms to predict the risk of complications over 1-5 years

Current disease whereabouts

We collect metabolic risk factor data to understand the current disease status.

How to avoid hazards

We provide clinically validated hints and tips to avoid complications.

We flag lifestyle interventions to the patients and drug interventions to the HCP.

Our approach

Revolutionise Using longitudinal data & AI to predict risk

Identify earlier identification of patients at risk of complications

Intervene enable earlier interventions for the HCP and patient

Company Gendius Limited
Alderley Park, Cheshire, UK
  • Proprietary AI risk predcition algorithms in CKD, CVD & Diabetes.
  • Over 7.5m data points.
  • Over 2,200 patients followed over 10 years.
  • £200k sales already.
  • CCG NHS pilots ongoing.
  • Global MSA with AstraZeneca.
  • MoU in place with B Grimm, leading healthcare provider in Thailand.

£8m pre-money

Investment sought

£2.5m for 24% equity (Q2 2021)

Use of funds
  • Supercharge commercialisation
  • Launch in the US & SE Asia
  • Further develop our AI capability – the secret sauce
  • Development of clinical validation
  • Launch additional diabetes platforms
  • Move into other chronic diseases
Existing investors


Catapult Ventures

Industry Venture Investors

HNWs and Crowdfunding


Rory Cameron – CEO. 25yrs+ sales & marketing in pharma with digital heath exit track record.

Chris Genders – Co-founder. 30yrs+ in healthcare, pharma, digital heath and diabetes.

Albert Nicholl – Chairman. 30yrs+ in MedTech sector.

Dr Natasha Patel – Lead Developer. 20yrs+ building & managing tech teams.

Forward investment strategy

£5.0m 2022 to support team and technology development.

Exit in 3–5 years.


The content of this communication has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this communication for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.

Find out more

To find out more or register your interest in this investment opportunity simply fill in and submit the form below and we will be in touch with you shortly.